Literature DB >> 2478180

Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour.

S Q Maddy1, G D Chisholm, A Busuttil, F K Habib.   

Abstract

The presence of specific and high affinity epidermal growth factor receptors (EGF-R) has been demonstrated in human prostate cancer (CaP). Scatchard analysis of the binding data revealed a linear plot consistent with a single class of binding sites with a mean dissociation constant (Kd) +/- s.d. = 1.6 +/- 0.4 nmol 1-1. Additionally the binding was specific for EGF since no other competitor than EGF was able to displace the binding of the labelled ligand from its receptor. Comparison of the concentrations of EGF-R in tissues from 19 patients with CaP with those measured in a group of 18 patients with benign prostatic hyperplasia (BPH) reveal that the expression of EGF-R was significantly higher in BPH (mean +/- s.d. = 125 +/- 7 fmol mg protein-1) than in CaP (52 +/- 11 fmol mg protein-1; P less than 0.01). Furthermore, in CaP the expression of EGF-R varied according to the histological grade of the cancer: well differentiated tumours demonstrated more receptors (84 +/- 13 fmol mg protein-1) than poorly differentiated tumours (22 +/- 5 fmol mg protein-1; P less than 0.01). Clearly the depletion in the expression of EGF receptors in CaP is a function of the histological grade of the cancer and as such EGF receptors could be used as a biochemical marker for tumour differentiation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478180      PMCID: PMC2247342          DOI: 10.1038/bjc.1989.216

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Growth factors from murine sarcoma virus-transformed cells.

Authors:  J E de Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

Review 3.  Epidermal growth factor.

Authors:  G Carpenter; S Cohen
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

4.  Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course.

Authors:  J E Pontes; T M Chu; N Slack; J Karr; G P Murphy
Journal:  J Urol       Date:  1982-12       Impact factor: 7.450

5.  Cell cycle variation in 125I-labeled epidermal growth factor binding in chemically transformed cells.

Authors:  R A Robinson; E L Branum; M E Volkenant; H L Moses
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

6.  Growth factor involvement and oncogene expression in prostatic tumours.

Authors:  C L Eaton; P Davies; M E Phillips
Journal:  J Steroid Biochem       Date:  1988       Impact factor: 4.292

7.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

8.  Incidental carcinoma of the prostate: selection for deferred treatment.

Authors:  L L Beynon; A Busuttil; J E Newsam; G D Chisholm
Journal:  Br J Urol       Date:  1983-12

9.  Cellular localisation of human epidermal growth factor receptor.

Authors:  B Gusterson; G Cowley; J A Smith; B Ozanne
Journal:  Cell Biol Int Rep       Date:  1984-08

10.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

View more
  9 in total

1.  Variability of immunohistochemical reactivity on stored paraffin slides.

Authors:  E O Olapade-Olaopa; E H MacKay; F K Habib
Journal:  J Clin Pathol       Date:  1998-12       Impact factor: 3.411

2.  Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy.

Authors:  B Ljungberg; M Gåfvels; J E Damber
Journal:  Urol Res       Date:  1994

Review 3.  Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer.

Authors:  J L Ware
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

4.  Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1.

Authors:  S W Hayward; R Dahiya; G R Cunha; J Bartek; N Deshpande; P Narayan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-01       Impact factor: 2.416

5.  Epidermal growth factor receptor content in rat prostatic adenocarcinoma: effects of endocrine treatment.

Authors:  J E Damber; A Bergh; B Assarsson; M Gåfvels
Journal:  Urol Res       Date:  1995

6.  Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.

Authors:  D Seth; K Shaw; J Jazayeri; P J Leedman
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer.

Authors:  E O Olapade-Olaopa; D K Moscatello; E H MacKay; T Horsburgh; D P Sandhu; T R Terry; A J Wong; F K Habib
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

8.  Expression of epithelial growth factor receptor in oral epithelial dysplastic lesions.

Authors:  Manickam Rajakili Chockalingam Rajeswari; Thillai Rajasekaran Saraswathi
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

9.  Epidermal growth factor and transforming growth factor alpha concentrations in BPH and cancer of the prostate: their relationships with tissue androgen levels.

Authors:  Y Yang; G D Chisholm; F K Habib
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.